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Abstract
Background: The treatment of intratumoral dentritic cells (DCs) commonly fails because it cannot evoke immunity in
a poor tumor microenvironment (TME). Modulated electro-hyperthermia (mEHT, trade-name: oncothermia) represents
a significant technological advancement in the hyperthermia field, allowing the autofocusing of electromagnetic
power on a cell membrane to generate massive apoptosis. This approach turns local immunogenic cancer cell
death (apoptosis) into a systemic anti-tumor immune response and may be implemented by treatment with
intratumoral DCs.
Methods: The CT26 murine colorectal cancer model was used in this investigation. The inhibition of growth of
the tumor and the systemic anti-tumor immune response were measured. The tumor was heated to a core
temperature of 42 °C for 30 min. The matured synergetic DCs were intratumorally injected 24 h following mEHT
was applied.
Results: mEHT induced significant apoptosis and enhanced the release of heat shock protein70 (Hsp70) in CT26
tumors. Treatment with mEHT-DCs significantly inhibited CT26 tumor growth, relative to DCs alone or mEHT
alone. The secondary tumor protection effect upon rechallenging was observed in mice that were treated with
mEHT-DCs. Immunohistochemical staining of CD45 and F4/80 revealed that mEHT-DC treatment increased the
number of leukocytes and macrophages. Most interestingly, mEHT also induced infiltrations of eosinophil, which
has recently been reported to be an orchestrator of a specific T cell response. Cytotoxic T cell assay and ELISpot
assay revealed a tumor-specific T cell activity.
Conclusions: This study demonstrated that mEHT induces tumor cell apoptosis and enhances the release of
Hsp70 from heated tumor cells, unlike conventional hyperthermia. mEHT can create a favorable tumor
microenvironment for an immunological chain reaction that improves the success rate of intratumoral DC
immunotherapy.
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Background
The tumor microenvironment (TME) is an important
factor in successful local treatment and in provoking a
systemic immunological response in cancer patients [1].
Dendritic cells (DCs) that infiltrate the TME are respon-
sible for the uptake of antigens in situ and maturation in
the draining lymph nodes, and the provide the basis for
effective anti-tumor T cell immune responses [2]. In situ
DC-based cancer immunotherapy with radiotherapy has
been utilized to treat cancer patients, but only a small
number of tumor regressions have been observed [3]. A
poor TME can cause DCs to differentiate into immuno-
suppressive regulatory DCs, which inhibit the effect of
cytotoxic T cells activation and promote tumor progres-
sion [4]. The function of DCs is mainly positively
affected by a microenvironment that contains fewer im-
mune suppression factors, more immune potentiating fac-
tors and an immunogenic hub in the tumor site [5, 6].
This fact previously motivated us to develop a new strat-
egy to improve the efficacy of in situ DC vaccination by
adding combining heat shock protein (Hsp) [7] or by
electro-gene therapy with cytokine [8]. How a therapy-
induced anti-tumor immunity should be manipulated is
not clearly known but immunogenic cancer cell death
(ICD) has emerged as the most important sign of a fa-
vorable immunogenic TME [6, 9]. Only a favorable
TME can provide the various important functional im-
munological cells and cytokines that are required for
immunotherapy [10, 11].
Hyperthermia has been used in cancer therapy for de-
cades. A branch of hyperthermia, known as modulated
electro-hyperthermia [12–15] (mEHT – trade name:
oncothermia) has been developed by the capacitive (im-
pedance-based) coupling of 13.56 MHz amplitude-
modulated radiofrequency energy at the tumor site [15].
The electric field energy may be selected and delivered to
the malignant cells by exploiting the larger amount of
ionic connective tissue around the tumor area, creating
massive apoptosis at mild temperatures (≦42 °C) [14–17].
In Europe, mEHT has been successfully utilized in clinical
treatment for over two decades [18–20]. Numerous retro-
spective studies of cancer patients have revealed that
mEHT can treat a very wide range of tumor lesions and
various types of tumor, demonstrating that the mEHT is a
feasible option for treating cancer [14]. It is generally ap-
plied to treat various forms of malignant tumor, such as
lung, liver, pancreas, brain, gastrointestinal, gynecological,
and other such tumors. Qin et al. demonstrated that
mEHT had an abscopal effect in experiments in vivo [21].
However, immature DCs that were used in Qin’s study
may have increased the tolerance of antitumor immunity
whereas mature DCs induce a strong antitumor immunity
when they interact with cancer cells that are undergoing
immunogenic cancer cell death (ICD) [22]. The
combination of mEHT and the intra-tumoral injection of
DCs may be able to provide a more sustained systemic
immunity, enhancing the abscopal effect [23]. We
hypothesize that mEHT is an ideal approach for changing
the TME from immune-suppressive to immune-
stimulatory. Mature DCs were utilized in this experiment
to eliminate interference with the DC maturation process
at tumor site and to observe the change in TME-induced
mDC activation.
Although hyperthermia, combined with an intratu-
moral injection of DC, reportedly evokes systemic im-
munity, two applications of a moderately high
temperature (43.7 °C for 1 h) are required to improve
the induce an effective acquisition of antigens following
three rounds of DCs treatment [24]. However, the
temperature is not easily reached in clinical practice by
conventional hyperthermia machine. Mild temperature
hyperthermia (>42 °C) cannot generate massive apop-
tosis or cause a damage-associated molecular pattern
(DAMP) in the tumor environment. The lack of release
of tumor antigens from apoptotic tumor cells may
dampen the effect of combined DCs and hyperthermia
[21, 25–27]. mEHT has been demonstrated to induce
massive apoptosis and a DAMP-related signal sequence
in colorectal cancer xenografts at mild temperatures
[28]. A favorable anti-tumor immune microenviron-
ment at a mild temperature may be more effective in
promoting an immunological cell death response [28].
For the above reasons, this work proposes that combin-
ing intratumoral DCs at mild temperature with mEHT
may be more effective in generating tumor cell apop-
tosis and DAMP and in providing a favorable immuno-
logical environment eliciting specific immunity. The
data obtained herein evidence that mEHT may change
TME immune phenotypes, including infiltrated leuko-
cytes and eosinophils, and be feasibly combined with
intra-tumoral DCs immunotherapy.
Methods
Cell lines and mice
CT26, a murine colon carcinoma cell line that is derived
from a BALB/c mouse, was purchased from the Culture
Collection and Research Center (Hsinchu,Taiwan), where
fresh batches are thawed every year. CT26 cells were
maintained in Dulbecco’s modified Eagle medium
(DMEM) was supplemented with 10 % fetal bovine
serum (FBS), 100 ng/ml of streptomycin, and 100 U/ml
of penicillin (Invitrogen). Female BALB/c mice were
obtained from the National Science Council Animal
Center, Taipei, Taiwan, and were used at between 6 and
8 weeks of age. This study was approved by the Institu-
tional Animal Care and Use Committee of the Shin
Kong Wu Ho-Su Memorial Hospital (Approval No.
0990827008).
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Modulated electro-hyperthermia treatment (mEHT)
Electromagnetic heating was conducted using capacitive-
coupling with an amplitude-modulated 13.56-MHz radio-
frequency (LabEHY, Oncotherm, Germany). The mEHT
technical details of the method can be found elsewhere
[29]. An in vitro heating model was established in an elec-
trode chamber (LabEHY in vitro applicator), which was
heated to 42 °C for 30 min at a mean power of 8 ~ 9 W.
The cells were placed in a chamber with a culture medium
at 42 °C for 30 min. Tumor implants in the right femoral
area of BALB/c mice were placed in the parallel electric
condenser of the heating circuit, as described elsewhere
[28]. The treatment groups were givena single shot of
mEHT for 30 min at a mean power of 1.5 W under
100 mg/kg Ketamine and 10 mg/kg Xylazine anesthesia.
Intratumoral temperature was maintained at ~ 42 °C on
the treated side of each mice, as measured using optical
sensors (Luxtron FOT Lab Kit, LumaSense Technologies,
Inc., California, USA). The subcutaneous temperature
underneath the electrode was maintained at 38 ~ 40 °C.
Apoptosis assay
Water bath-treated and mEHT-treated CT26 cells were
cultured for 24 h, then trypsinized, and washed twice
with PBS. Apoptosis was verified using an Annexin V
Apoptosis Kit (BD Pharmingen), following the manufac-
turer’s instructions. Briefly, tumor cells were washed
three times with PBS; then, some cells were analyzed im-
mediately for apoptosis using Annexin V/PI staining.
Washed cells were supplemented with 1 % BSA and then
stained directly with 10 μL of PI and 2.5 μL Annexin V-
FITC, following the addition of 222.5 μL of binding
buffer. Immediately after 10 min of incubation in the
dark on ice, the cells were analyzed by flow cytometry.
The percentage of positive cells was determined using a
FACSCalibur cytometer and Cell Quest Pro software
(Becton Dickinson, Mountain View, CA).
Western blot analysis
For protein analysis, the water bath-treated control and
mEHT-treated CT26 cells were lysed for 5 min at room
temperature in a buffer of 150 mM NaCl, 50 mM Tris
(pH 8.0), 5 mM EDTA, 1 % (v/v) Nonidet p-40, 1 mM
phenylmethylsulfonyl fluoride, 20 μg/mL aprotinin, and
25 μg/mL leupeptin (Sigma). The total protein concen-
tration was measured using the Bio-Rad protein assay
reagent. Cell lysates (100 μg) were electrophoresed on a
12 % polyacrylamide gel, transferred onto an Immobilon-
P PVDF membrane (Millipore, Bedford, MA), and blocked
in PBS-Tween 20 and 10 % nonfat milk for 2 h at room
temperature. The filter was incubated with specific anti-
bodies to anti-Hsp70 (Santa Cruz Biotechnology, Santa
Cruz, CA) and anti-HMGB-1 (Abcam, Cambridge, MA,
USA) for 2 h at room temperature in PBS-0.05 %
Tween 20 that contained 5 % nonfat milk, followed by
1 h incubation at room temperature with horseradish
peroxidase-conjugated secondary antibodies (Jackson
ImmunoResearch Laboratories, West Grove, PA) in the
same buffer. Blots were developed using a chemilumin-
escent detection system (ECL; GE Life Science,
Buckinghamshire, UK).
Hsp70 release assay
mEHT treated CT26 cells were cultured for 24 h. The
culture supernatants were harvested and Hsp70 was
measured by using an enzyme-linked immunosorbent
assay (ELISA) (Enzo Life Sciences, Farmingdale, USA). A
Multiskan Plus (Thermo Scientific, Hudson, NH, USA)
was utilized to measure absorbance at 450 nm.
Generation of bone marrow-derived dendritic cells
Bone marrow-derived DCs (BM-DCs) were produced as
described elsewhere [9]. Briefly, BM-DCs were isolated
from BALB/c mice by culturing red blood cell-depleted
BM cells in a complete medium (RPMI 1640 that was
supplemented with 10 % FBS, L-glutamine, and 5 mM
2-mercaptoethanol) that contained 20 ng/ml of recom-
binant mouse GM-CSF (Peprotech, Rocky Hill, NJ,
USA) at 37 °C in a humidified atmosphere with 5 % CO2
and fed every third day with a medium that contained
fresh GM-CSF. On day nine of the culture, the DCs
were mixed with 10 μg/ml AH1 (SPSYVYHQF) that had
been manufactured at 95 % purity by AnaSpec (Fremont,
CA) and 50 μg/ml Hsp70 which was prepared in our la-
boratory as described elsewhere [7] for 24 h. On day ten
of the culture, non-adherent cells were harvested,
washed once in a complete medium, and examined to
evaluate the expression of the DC surface markers
(MHC class II molecule I-Ad/I-Ed, CD80 (B7-1), CD86
(B7-2), CD11c, and DEC205). The BM-DCs (5–10 × 105)
were stained with 50 μL of FITC-conjugated antibodies
in phosphate-buffered saline (PBS) that contained 1 %
bovine serum albumin (BSA) and 0.1 % azide, which was
also used as the washing buffer, before being subjected
to fluorescence-activated cell sorting (FACS) analysis
using a FASCalibur flow cytometer (BD Bioscience, San
Diego, California, USA). Cells were stained with the
corresponding isotype-matched control IgG (BD
Pharmingen, San Diego, CA, USA). Endocytic activity
was quantifiedby incubating cells for 2 h with FITC-
dextran (100 μg/ml) (Sigma) at 4 °C or 37 °C. Cells were
washed extensively with PBS, before being subjected to
FACS analysis. Non-specific binding of FITC-dextran to
the cell surface was measured by incubating the cells at
4 °C [30]. The percentage of positive cells was obtained
using a FACSCalibur cytometer and Cell Quest Pro soft-
ware (Becton Dickinson, Mountain View, CA).
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Animal study
On day zero, the right femoral areas of BALB/c mice
were injected subcutaneously with 5 × 105 CT26 tumor
cells. On day 14 following injection, the mice received
local mEHT treatment (as described above), and then,
on the following day, 5 × 105 syngeneic DCs or PBS in
25 μL were injected into the right femoral tumor area.
Each group comprised ten mice. Sampling was carried
out 48 h following treatment, using three mice in each
group. Each excised tumor was fixed in 10 % formalin,
dehydrated, and embedded in paraffin wax (FFPE). The
sizes of the tumors in the other seven mice in each
group were measured at least three times weekly: length
(L) and width (W) were recorded and the tumor vol-
umes were calculated as L ×W2/2. To evaluate whether
specific immunologic memory responses were generated
in mice that bore CT26 tumor cells, the mice were re-
challenged with 1 × 105 tumor cells in the other flank
30 days following the first tumor inoculation [9]. The
mice were examined three times weekly to evaluate
tumor development for 30 days after tumor cell trans-
plantation or the first inoculated tumor growth until the
tumor was more than 2 cm in diameter.
Cytotoxicity T lymphocyte (CTL) assay
On day 30 following tumor injection, the mice were
killed and their spleens harvested. Erythrocyte-depleted
splenocytes (1 × 106 cells/ml) were cultured for five days
in vitro using mitomycin C-treated CT26 tumor cells
(1 × 106 cells/ml) in 24-well plates, during which time
50 IU/ml of recombinant human IL-2 (Proleukin; Novar-
tis Pharmaceuticals, East Hanover, NJ) was added daily.
On day five, the cells were collected; dead cells were
removed on a density gradient, and the viable cells were
tested to evaluate specific cytotoxicity using LDH-
release assay (Promega, Madison, WI, USA). The
percentage-specific cytotoxicity was calculated as 100 x
[(experimental release – spontaneous release)/(maximal
release – spontaneous release)].
Enzyme-linked immunosorbent spot (ELISPOT) assay
The ELISPOT assay was conducted using a Mouse IFN-
γ Development Module kit (R&D System), following the
manufacturer’s instructions. Splenocytes were prepared
as described for use in the CTL reactions. The harvested
splenocytes (1 × 105 in 100 μL) were then mixed with
100 μL of CT26 tumor lysate (50 μg of protein/ml) in
each well of a 96-well filtration plate (MultiscreenTM
HTS) that had been previously coated with capture anti-
bodies (1:60 dilution). The negative controls were the
medium alone and the splenocytes alone and the posi-
tive control was splenocytes plus 20 μg/ml of Con A.
After incubation overnight at 37 °C, color was developed
using the streptavidin-alkaline peroxidase and BCIP/
NBT that was provided in the ELISPOT kits. The spots
were counted visually under a dissection microscope;
the numbers of spots in the test samples (splenocytes +
tumor lysate), spots obtained using splenocytes alone,
and spots obtained using medium alone were calculated.
Immunohistochemistry and Luna stain
To conduct immunohistochemical studies, the tumor
was resected and fixed in 10 % formalin for 24 h. To
stain the sections immunohistochemically, paraffin sec-
tions were deparaffinized in xylene and rehydrated in a
graded alcohol series, treated with 3 % H2O2 for 10 min,
and boiled in a citrate buffer (pH 6) for 30 min (anti-F4/
80 antibody, Bioss bs-7058R, anti-CD45 antibody, Bioss
bs-0522R), before immunoblock (Bio TnA, TAHC03)
was applied to prevent non-specific binding for 60 min
at room temperature. The sections were incubated with
rabbit anti-F4/80 antibody (diluted 1:100) and anti-
CD45 antibody (diluted 1:100) for one hour at 37 °C,
and analyzed by Mouse/Rabbit Probe HRP labeling
(BioTnA, TAHC03) for 30 min at room temperature.
Peroxidase activity was developed in a diaminobenzi-
dine- H2O2 solution (Bio TnA, TAHC03) for 10 min at
room temperature. The sections were then counter-
stained with hematoxylin. All stained slides were exam-
ined by two pathologists who were blind to the
treatment group data. The percentage of positively
stained cell membranes or cytoplasm was obtained by
microscopically examining the entire tissue at high mag-
nification (×400). The numbers of positive cells was cal-
culated in ten fields. The Luna protocol was performed
as described elsewhere with slight modifications [31].
The sections were immersed in working Hematoxylin-
Biebrich (Sigma, Cat # H-3136 and Acros, CI 26905, re-
spectively) scarlet solution (for five minutes), and then
dipped (∼8x) in 1 % acid alcohol and rinsed in tap water.
The sections were then dipped (∼5x) in lithium carbon-
ate solution until they turned blue and washed in run-
ning tap water (for two minutes). The numbers of
eosinophil on the stained slide were calculated in ten
fields (x400).
Statistical analysis
All results were compared using an unpaired t test (two-
tailed) or one-way ANOVA. Differences were considered
statistically significant at a P value of less than 0.05
Results
mEHT induced more apoptotic cell death than water
bath-induced hyperthermia in CT26 cells
The apoptotic efficacy of hyperthermia that was induced
by a water bath or mEHT in CT26 cells was evaluated
using an apoptosis assay kit. mEHT treatment signifi-
cantly increased the percentage of apoptotic cells
Tsang et al. BMC Cancer  (2015) 15:708 Page 4 of 11
(35.10 %) above that of the 37 °C control (2.76 %) or the
water bath control (2.98 %, p < 0.05) (Fig. 1). This result
suggests that mEHT increased the susceptibility of CT26
cells to apoptosis, whereas the water bath did not.
mEHT promoted the generation and release of Hsp70 in
CT26 cells
Since the expression of Hsp70 is a characteristic of
hyperthermia treatment, the intracellular amount of
Hsp70 and the release of Hsp70 following mEHT and
water bath-induced hyperthermia were investigated.
Whole-cell extracts were prepared for western blot
against Hsp70. The released Hsp70 was collected from
the cell culture supernatant and assayed by ELISA. Both
water bath and mEHT treatment increased the expres-
sion of Hsp70 in CT26 cells (Fig. 2a). Interestingly, only
mEHT significantly increased the release of Hsp70 for
hyperthermia (Fig. 2b). Another danger signal, high mo-
bility group box 1 (HMGB1) protein, did not show any
difference in mEHT as compared to water bath-induced
hyperthermia (Fig. 2a). Those data revealed that mEHT
induced greater Hsp70 responses at a cellular level than
did water bath-induced hyperthermia.
AH1 and Hsp70 induce maturation of BM-DCs
A CT26-derived epitope (AH1) [32] that was presented
by H-2Dd and Hsp70 was used as an antigen to stimu-
late DC maturation, as described elsewhere [7]. The
maturation of DCs was quantified from the expression
of specific cell surface markers, and the relevant data
were collected from three independent experiments.
Additional file 1: Figure A reveals that a high proportion
of the cells were DC-positive for CD11c (MFI: 51.20 ±
20.04), MHC class II (MFI: 74.43 ± 15.62) and CD80
(MFI: 32.45 ± 7.91) antigens, and that AH1 and Hsp70
upregulated the expression of the mouse DC maturation
markers MHC class II (MFI: 283.33 ± 119.30) and CD80
(MFI: 108.79 ± 26.60) on BM-DCs. Immature DCs ex-
hibit potent endocytotic activity, which declines upon
maturation. The endocytotic activity of the BM-DCs was
evaluated before and after AH1 and Hsp70 treatment by
measuring the phagocytosis of mannose-receptor-
mediated FITC-Dextran. The uptake was significantly
lower (P < 0.05) following AH1 and Hsp70 treatment
than before (35.2 % ±11.4 % versus 85.9 % ±7.9 %)
(Additional file 1: Figure B).
Combination of both local and systemic mEHT induced
anti-tumor effect of DC therapy in vivo
First, whether local mEHT-DC immunotherapy could
induce an either local therapeutic effect or systemic anti-
tumor effects was tested outside of the treatment field in
tumor-bearing mice. Based on the hypothesis that the
indirect antitumor effects of DC are mediated by its abil-
ity to promote cross-priming and, therefore, trigger sys-
temic antitumor immunity, mEHT was administered to
mice before DC injection to change the TME and facili-
tate this process. Tumors were treated to quantify the
direct therapeutic effect of mEHT-DC therapy (Fig. 3a)
by injecting DCs into the tumor site 24 h following
mEHT treatment. Two days later, three tumors were re-
moved for immunohistochemical staining, and the sizes
of the tumors in the rest of the mice were measured
every two or three days weekly. mEHT-DC therapy sig-
nificantly delayed local tumor growth (Fig. 3a), and
complete tumor regression was observed in five out of
seven mice in this group. Interestingly, mEHT treat-
ment alone also caused a significant growth delay rela-
tive to the control mice or mice treated with DC alone
(P < 0.05); complete tumor regression was observed in two
out of seven mice in the mEHT-treatment-alone group.
mEHT-DC treatment improves immunogenicity
To evaluate both the direct and systemic effects of
mEHT-DC therapy, a rechallenge model was utilized in
which mice had one tumor first and were inoculated
with a secondary tumor one month later. All mice that
were originally treated with mEHT-DC showed complete
rejection of a secondary rechallenge (Fig. 3b). In con-
trast, five out of seven mEHT-treated mice and four out
of seven DC-treated mice rejected the rechallenge of
CT26 cells. All of the untreated control mice grew the
rechallenge tumor within 12 days. This result indicates
that mEHT-DC treatment induces an effective antitumor
memory response.
Fig. 1 Apoptosis in mEHT-treated CT26 cells. One and a half million
CT26 cells were heated to 42 °C for 30 min using LabEHY or a water
bath (control). The apoptosis of CT26 cells after 24 h of hyperthermia
treatment was analyzed using Annexin-V assay. (*, p < 0.05; n = 3)
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mEHT-DC therapy increases number of tumor-infiltrating
leukocytes
To elucidate the anti-tumor immune response that is
generated by treatment with mEHT and DC, tumors
from the treated and control mice were extracted and
processed for immunohistochemical analysis two days
after treatment. Tumor-infiltrating CD45+ leukocytes
and F4/80+ macrophages were identified. The presence
of tumor-infiltrating CD45+ leukocytes was significantly
higher in mice that had been treated with mEHT-DC
than in those that had been treated with mEHT alone,
those that had been treated with DC alone and the con-
trol mice. mEHT alone significantly increased the infil-
tration of CD45+ leukocytes over that achieved using
DC alone or evident in the control mice (Fig. 4a). An in-
crease in tumor-infiltrating F4/80+ macrophages was ob-
served following the combined administration of
mEHT/DC (Fig. 4b). This result demonstrates that
mEHT induced an inflammatory environment and that
combined treatment strengthened this inflammatory re-
sponse. In addition, tumor-associated eosinophilia is fre-
quently observed in some cancers. Several studies have
shown that eosinophils are attracted into tumors by
chemotactic factors [33, 34]. However, the role of infil-
trating eosinophils in tumor is unclear. Recently, a pub-
lished study demonstrated that activated eosinophils
caused substantial changes in the tumor microenviron-
ment, including the polarization of macrophages and
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Fig. 3 Inhibition of tumor growth and rechallenge inoculation. a Mice in different groups were injected with 5 × 105 CT26 tumor cells
(subcutaneously) in right femoral area on day zero and treated with mEHT on day 14, before receiving DC injection on day 15. Data obtained
from each mouse after tumor-cell inoculation (n = 7) were plotted. b A secondary rechallenge with CT26 tumor cells was administered to mice
30 days after first injection with DC alone or following mEHT or mEHT-DC therapy. Contra-lateral flanks of mice in treated groups and untreated
control BALB/c mice were inoculated subcutaneously (1 × 105 parental CT26 cells). Percentage of mice that developed tumors at contra-lateral site
was obtained using Kaplan–Meier method. (n = 7 mice per group.)
Fig. 2 Expression and release of Hsp70 following hyperthermia treatment. One and a half million CT26 cells were heated to 42 °C for 30 min
using LabEHY or a water bath (control). a After 24 h of incubation, cells were harvested for western blot analysis of Hsp70 or HMGB1 protein
in lysates of CT26 (control) (37 °C), a water bath (control) (42 °C) or mEHT. β-actin was used as an internal control. b After 24 h of incubation,
supernatants were harvested and concentration of Hsp70 was measured using ELISA (n = 3). Data are presented as mean +/− SD from three
independent experiments. * indicates p < 0.05
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normalization of the tumor vasculature, which are
known to promote tumor regression [35]. Therefore, eo-
sinophils were examined herein by Luna staining. Ac-
cording to Fig. 4c, the presence of tumor-infiltrating
eosinophils was significantly higher in the mice that
were treated with mEHT-DC than in the other groups.
This result demonstrates that mEHT recruited eosino-
phils into the tumor tissue and might have induced an
inflammatory response.
mEHT-DC therapy induced cytotoxic antigen-specific
CD8+ effector cells
Seven days following DC injection, two other mice were
sacrificed and the induction of AH1-specific IFN-γ–pro-
ducing CD8+ cells was tested after the T cells were re-
stimulated with the AH1 recombinant protein in an
ELISPOT assay. The cytolytic activity of responding T
cells was tested directly on AH1-positive CT26 target
cells in an LDH-release assay. As shown in Fig. 5,
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Fig. 4 Areas of tumor infiltrated by immune cells after mEHT and DC treatment. Representative images of immunohistochemical straining revealed
that quantities of CD45 (a) and F4/80 (b) were increased in tumors that were treated with DC and mEHT, either alone or in combination. Proportion of
positive cells in one field that was randomly selected from ten fields, was calculated. c Amount of eosinophil increased significantly upon treatment of
tumor; error bars represent standard errors. (***) P < 0.001 (t-test) relative to control. EH: electro-hyperethermia
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specific cytotoxicity was significantly higher in mice
that were co-treated with mEHT and DC than in those
that were treated with DCs alone, those that were
treated mEHT alone or the control mice after spleno-
cytes had been stimulated with AH1 recombinant pro-
tein (P < 0.05). The lytic activity of the cultured spleen
cells correlated strongly with the degree of inhibition of
tumor growth in each group, as presented in Fig. 3.
mEHT-DC therapy significantly increased the T cell-
mediated cytotoxicity over that observed in control
mice, while DC alone had no significant effect.
Figure 6a presents representative results of the ELI-
SPOT assays of cells that were pulsed with AH1 recom-
binant protein. The number of IFN-γ-secreting CD8+
T-cells in mice that were co-treated with mEHT and
DC significantly exceeded the corresponding numbers
in mice that were treated with DCs alone, mEHT alone
or the control (Fig. 6b; P < 0.001, one-way ANOVA).
These results indicate that the intra-tumoral injection
of DCs combined with mEHT therapy induced stronger
antigen-specific immunity than did treatment with DCs
alone or mEHT alone.
Discussion
This study found that the combination of mEHT at a
clinical achievable temperature (42 °C) with the intra-
tumoral injection of DCs not only elicits a local antitu-
mor response but also induces a systemic anti-tumor
immune response. A tumor-specific T cell response was
evoked. The ability of mEHT to induce apoptosis in a
high percentage of tumor cells and enhance the release
of Hsp70 is believed to be a key contributor to the
tumor-specific immune response. In our previous study,
co-injection of rHsp70 and DCs was found to turn
Fig. 5 Tumor-specific CTLs. Mice in various groups were injected
with 5 × 105 CT26 tumor cells subcutaneously on day zero and with
mEHT on day 14, before being given DC injection on day 15. On
day 30 following tumor injection, splenocytes were harvested for
CTL assay. Cytotoxic activity of splenocytes was determined by
LDH-release assay at various effector/target cells (E/T) ratios
(a)
(b)
Control DC mEHT mEHT + DC
Fig. 6 ELISpot assays. a Representative results of ELISpot assay of mice splenocytes that were pulsed with AH1. Top two rows, 2 × 105
splenocytes/well; bottom two rows, 105 splenocytes/well. PC: positive control, splenocytes treated with ConA (5 mg/ml) for 24 h. NC: negative
control, splenocytes treated with BSA for 24 h. b Numbers of IFN-γ-secreting T-cells in DC-treated and mEHT + DC-treated mice significantly
exceeded those in mice treated with mEHT alone and untreated control mice. Error bars represent standard errors. (***) P < 0.001 (t-test) relative
to control. EH: electro-hyperethermia
Tsang et al. BMC Cancer  (2015) 15:708 Page 8 of 11
radiation-induced local apoptosis into a systemic anti-
tumor immune response. Co-injection of rHsp70 and
DCs into the irradiated tumor site caused a more potent
anti-tumor immune response than did the injection of
DCs alone [7]. In this study, mEHT caused a heated
tumor to release more Hsp70 into extracellular spaces
than did other hyperthermic methods. The release of
Hsp70 served as a danger signal that made the TME a
more immunologically responsive milieu, in which infil-
tration by eosinophils.
Mukhopadhaya et al. reported that localized hyper-
thermia, following by heating in a water bath at 43.5 °C,
combined with intratumoral DC induced systemic anti-
tumor immunity [24]. Heat treatment (>43.5 °C) induces
both apoptosis and necrosis and the release of Hsp70
from cancer cells and triggers DC activation. However,
several points must be addressed. First, heating by a
water bath cannot be used in clinical practice. Heating a
localized tumor to 43 °C using conventional hyperther-
mia machines is very difficult. In the experiment in this
study, hyperthermia that was generated using a water
bath at 42 °C induced only a limited apoptotic or nec-
rotic effect in cancer cells. Another radiofrequency ma-
chine, operated at 42 °C for 30 min, also failed to have
cause significant apoptosis in cells (unpublished data).
Only mEHT induced significant apoptotic cell death at
42 °C for 30 min. Accordingly, the combination of
mEHT with intratumoral DC immunotherapy should be
clinically feasible. We have previously reported that the
intratumoral injection of immature DCs into the irradi-
ated tumor (RT-DC treatment) elicits tumor-specific im-
munity in hepatocellular carcinoma patients [3]. The
present study recommends a future clinical trial of a
combination of mEHT, intra-tumoral injection of DCs
and radiotherapy.
The use of mEHT treatment as adjuvant for DC ther-
apy to induce immunogenic apoptotic cell death by has
recently been examined [21, 36]. However, the incuba-
tion of stressed, apoptotic tumor cells with syngeneic
DCs is generally not strong enough to generate protect-
ive immunity, suggesting that the uptake of apoptotic
cells by DCs alone may not be sufficiently efficient to ac-
tivate an immune response, as described by others [37].
In this study, DC alone was not effective in inducing an
immune response. The suppressive monocytes that are
formed by a CT26 tumor have an important role in
general immunosuppression [38]. These suppressive
monocytes may inhibit the function of therapeutic DC.
Therefore, the secondary signals that are required to ac-
tivate DC function are induced by danger molecular pat-
tern proteins, such as calreticulin, HSPs, and the
HMGB1 [39]. mEHT provides danger molecular pattern
proteins and induces inflammatory signals in tumor mi-
croenvironments [28]. Apoptotic cells cannot effectively
activate DC activation in the absence of inflammatory sig-
nals [37, 40, 41]. Candido et al. [42] found that intratu-
moral administration of DC can partially inhibit the
growth of an established tumor, but the co-administration
of inflammation cytokine (TNF-α) strengthens the
DC-mediated anti-tumor effect, consistent with our
observations.
mEHT reversed the immunosuppressive microenviron-
ment to an inflammatory environment and induced a DC-
mediated anti-tumor immune response [21]. The inflam-
matory environment herein was evidenced by the infiltra-
tion of CD45+ cells and F4/80+ cells (Fig. 4). Tumor-
infiltrating CD45RO+-cell density has been identified as a
prognostic biomarker that is associated with the longer
survival of colorectal cancer patients [43]. mEHT im-
proves the expression of this prognostic biomarker.
Changing the TME into an inflammatory environment
is important in ensuring that the DCs function in a
manner that triggers systemic immunity and that the ef-
fector T cells adequately kill tumors. Although several
studies have shown that DC therapy induces immune re-
sponses in cancer patients, few reports have demon-
strated any clinical benefit of DC treatment perhaps
because of the inhibitory effect of the TME. To improve
the efficacy of DC therapy, the immunosuppressive sta-
tus of the TME must be reprogrammed [44]. Immune
checkpoint blockage therapy was recently shown to have
a promising therapeutic effect on cancer patients [45].
The combination of positive immunotherapy with an
anti-negative immune checkpoint inhibitor is a synergis-
tic strategy [46]. The success of immune check point
therapy demonstrates that elimination of the inhibitory
pathways that block effective antitumor T cell responses
is important in cancer therapy. However, the removal of
inhibitory pathways from the immune system does not
suffice to cure all of a cancer: increasing the number of
immunopotentiation tumor-infiltrating cells, including
CD45-positive leukocytes [46] and eosinophils, may be
equally important [35]. However, a tumor tissue that
lacks immunological markers may represent a nonim-
munologic TME. The TME must be turned into an im-
munologic TME before DC therapy can activate T cells.
Reciprocally, active T cells depend on an immunological
TME to have a positive clinical effect. Therefore, com-
bined treatment with mEHT and DCs should help to es-
tablish OR an immunogenic TME that has a clinical
benefit for patients, independently of whether the preex-
isting tumor was immunogenic or nonimmunologic.
Owing to the clinical feasibility of mEHT, this result sug-
gests future clinical applications.
Conclusion
In summary, mEHT is more effective in combined im-
munotherapy than is conventional hyperthermia in a
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clinically viable temperature range. Hyperthermia-induced
local tumor apoptosis and release of Hsp70 can be trans-
lated into a systemic anti-tumor immune response. Since
mEHT treatment alone is not sufficiently powerful to gen-
erate a systemic specific anti-tumor immune response, the
best treatment strategy may be to increase the immuno-
genicity of non- or weakly immunogenic tumor cells by
promoting their DC function. Further clinical investiga-
tion will be initiated accordingly.
Additional file
Additional file 1: Figure A. (a) Representative flow cytometric analysis
on immature and mature DCs. The purple histograms represent the
isotype-matched control, and the red line histograms represent staining
with specific antibodies. *MFI represents the mean fluorescence intensity,
which are expressed on the right upper corner of each histogram. Error
bars represent standard errors. (b) Histogram plot of MFI. (*) P < 0.05, (**)
P < 0.01 (t-test) compared with the immature DC. Figure B. Endocytotic
activity was measured by flow cytometry in DCs generated from bone
marrow cultured for 9 d with 20 ng/ml of GM-CSF; mDCs obtained from
iDCs were incubated with 10 g/mL of AH1 and 50 g/mL of Hsp70 for 24
h and reacted with 100 mg/mL of FITC-Dextran at 4°C (purple) or 37 °C
(green line) for 2 h before analysis. This result was represented from one
of three independent experiments. (DOCX 608 kb)
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